BridgeMD
New treatment option for Liver Transplantation
Official title HOPE Against Cancer Recurrence in HCC
ClinicalTrials.gov ID: NCT06717919
What this study is testing
- What it's testing
- Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult recipients (\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnetic...
- within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point...
- written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC
You likely can't join if
- Donation after circulatory death (DCD) liver grafts
- Combined liver transplants
- Partial liver transplants
- Combined or mixed hepatocellular cholangiocarcinoma (cHCC-CCC) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant
- Systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors
- Post-transplant treatment with mTOR inhibitors
See the full eligibility criteria
- Adult recipients (\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnetic resonance imaging or computer tomography of the liver or biopsy...
- within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point of liver transplantation,
- written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC
- Donation after circulatory death (DCD) liver grafts
- Combined liver transplants
- Partial liver transplants
- Combined or mixed hepatocellular cholangiocarcinoma (cHCC-CCC) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant
- Systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors
- Post-transplant treatment with mTOR inhibitors
- Acute and unexpected medical contraindications
- Pregnancy
- Cold storage time of \> 10 hours (both study arms)
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
- Cleveland, Ohio, United States
- Innsbruck, Austria
- Vienna, Austria
- Leuven, Belgium
- Woluwe-Saint-Lambert, Belgium
- Prague, Czechia
- Copenhagen, Denmark
- Lyon, France
- Essen, Germany
- Hamburg-Eppendorf, Germany
- Hanover, Germany
- Heidelberg, Germany
- Mainz, Germany
- München, Germany
- Milan, Italy
- Padova, Italy
- Rome, Italy
- Udine, Italy
- Kaunas, Lithuania
+ 15 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States; Cleveland, Ohio, United States; Innsbruck, Austria; Vienna, Austria; Leuven, Belgium; Woluwe-Saint-Lambert, Belgium and 29 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.